Data on Novantrone to be presented at Neurology conference

They include:

Oral Presentations: -- Safety and Efficacy of Combination Therapy with Interferon Beta-1b and Mitoxantrone in Worsening MS using Monthly Gadolinium Enhanced MRI Abstract #S23.004 Tuesday, April 16, 4:30-4:45 p.m. Location: A 201/5 Presenter: Douglas Jeffery, M.D., Wake Forest University Baptist Medial Center

-- Safety Profile of Mitoxantrone in a Cohort of 802 Multiple Sclerosis Patients Abstract # S23.005 Tuesday, April 16, 4:45 p.m. Location: A 201/5 Presenter: Gilles Edan, M.D., Department of Neurology, Centre Hospitalier Universitaire, Rennes, France

Posters: -- The Registry To Evaluate Mitoxantrone Effects in Worsening MS (RENEW) Abstract # P06.086 Thursday, April 18, 3:00 p.m. Location: Exhibit Hall B Presenter: Donald E. Goodkin, M.D., Immunex Corporation

-- Safety and Tolerability of Mitoxantrone Use in MS: Phase IV Experience in 170 Patients Receiving Single or Combination Treatment Abstract #PO6.086 Thursday, April 18, 2002, 3:00 p.m. Location: Exhibit Hall B Presenter: Saud A. Sadiq, Multiple Sclerosis Research and Treatment Center, St. Luke's Hospital Roosevelt Center

For assistance in arranging an interview with one of the above listed researchers, or a representative of Immunex, contact Kim Davis at Immunex at 206-389-4024.